Sugi Predict

Sugi Predict / Targets / PROC

PROC

Vitamin K-dependent protein C · P04070 · PROC on Sugi Atlas →

9,393 patent compounds predicted against PROC, 7,426 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL478372 SCHEMBL478372 1.00 2/20
SCHEMBL478373 SCHEMBL478373 1.00 2/20
SCHEMBL478556 SCHEMBL478556 1.00 2/20
SCHEMBL478558 SCHEMBL478558 1.00 2/20
SCHEMBL478472 SCHEMBL478472 0.89 2/20
SCHEMBL478474 SCHEMBL478474 0.89 2/20
SCHEMBL478731 SCHEMBL478731 0.88 2/20
SCHEMBL478733 SCHEMBL478733 0.88 2/20
SCHEMBL478734 SCHEMBL478734 0.88 2/20
SCHEMBL481003 SCHEMBL481003 0.88 2/20
SCHEMBL481210 SCHEMBL481210 0.88 2/20
SCHEMBL481211 SCHEMBL481211 0.88 2/20
SCHEMBL478442 SCHEMBL478442 0.87 2/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL1188533) 0.87 2/20
SCHEMBL478589 SCHEMBL478589 0.87 2/20
SCHEMBL478728 SCHEMBL478728 0.87 2/20
SCHEMBL478729 SCHEMBL478729 0.87 2/20
SCHEMBL478948 SCHEMBL478948 0.85 2/20
SCHEMBL478949 SCHEMBL478949 0.85 2/20
SCHEMBL478950 SCHEMBL478950 0.85 2/20

Clinical trials — most relevant to PROC by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Assessment of Coagulation Factor Levels in Left Ventricular Device (LVAD )Patients Following Temporary Warfarin Reversal With Four Factor Prothrombin Complex Concentrate (4F-PCC) PHASE4UNKNOWN
Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography PHASE4UNKNOWN
Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal PHASE4COMPLETED
Study Use of PPSB-SD and VP-VI in Patients With Anticoagulant Therapy and Undergoing Acute CPB Surgery PHASE4COMPLETED
AntiCoagulants and COGnition PHASE4UNKNOWN
PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A） PHASE4RECRUITING
Efficacy and Safety Study of Protein C Concentrate in Subjects With Severe Congenital Protein C Deficiency PHASE2/PHASE3COMPLETED
Dose Defining Study for the Administration of Vitamin K2 Supplements in Hemodialysis Patients PHASE3COMPLETED
Humacyte's HAV for Femoro-Popliteal Bypass in Patients With PAD PHASE2COMPLETED
Fiix-prothrombin Time for Monitoring Warfarin PHASE2COMPLETED
Study of Avatrombopag for Temozolomide-induced Thrombocytopenia in Glioma (APATIT-G) EARLY_PHASE1WITHDRAWN
Randomized Controlled Clinical Trial to Investigate Effects of Vitamin K2 in COVID-19 nanCOMPLETED
Haemostatic Imbalance in Patients With Chronic Liver Disease nanUNKNOWN
Evaluation of Factors II, VII, IX, X, and Proteins C and S, Following High-dose Vitamin K Supplementation nanCOMPLETED
FFP Versus PCC in Intracranial Hemorrhage nanWITHDRAWN
Study to Develop a Reliable Nomogram That Incorporates Clinical and Genetic Information nanCOMPLETED
Correlation Between PT and INR to Factor 7 nanUNKNOWN
Analysis of the Coagulopathy Developed by COVID-19 Infected Patients nanCOMPLETED
Vascular Ultrasound Versus Intravascular Ultrasound for Diagnosing Iliac Vein Obstruction nanUNKNOWN
Diagnostic Accuracy Study of a Point-of-Care Test for Coagulation Function nanUNKNOWN
The DANish COronary DEcalcification (DANCODE) Trial nanACTIVE_NOT_RECRUITING
Adjuvant Therapy With Thalidomide After Curative Resection of Hepatocellular Carcinoma nanUNKNOWN
Protein S and Myocardial Infarction nanCOMPLETED
The OK Daily Study nanNOT_YET_RECRUITING
Prevention of Thrombosis Recurrence in Patients With Low Circulating Levels of Antithrombin. nanUNKNOWN
The Prevalence of Sub Optimal Anti Coagulation nanUNKNOWN
Assessment Of Liver and Spleen Fibrosis in Patients With Gaucher Disease Using Fibroscan nanUNKNOWN
Study of Abnormal Blood Clotting in Children With Stroke nanCOMPLETED
Effect of Vitamin K in Critically Ill Patients nanCOMPLETED
Prophylaxis Against DVTs After Primary Hip and Knee Replacement Surgery nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PROC binder may also engage these)

ProteinNameSimilarity
Q9GLP2 — 1.000 Q9GLP2 →
F7 Coagulation factor VII 1.000 landscape →
Q2F9P2 — 1.000 Q2F9P2 →
P00745 — 1.000 P00745 →
P31394 — 0.999 P31394 →
Q28278 — 0.998 Q28278 →
Q28661 — 0.998 Q28661 →
P33587 — 0.998 P33587 →
Q2F9P4 — 0.996 Q2F9P4 →
D3ZTE0 — 0.995 D3ZTE0 →
Q80YC5 — 0.995 Q80YC5 →
P70375 — 0.995 P70375 →
P00743 — 0.994 P00743 →
P22891 — 0.994 P22891 →
P98139 — 0.993 P98139 →
Q3UZ09 — 0.992 Q3UZ09 →
Q8K3U6 — 0.992 Q8K3U6 →
Q9CQW3 — 0.992 Q9CQW3 →
O97507 — 0.990 O97507 →
Q6IE64 — 0.990 Q6IE64 →
F10 Coagulation factor X 0.989 landscape →
P18292 — 0.989 P18292 →
Q04962 — 0.988 Q04962 →
TMPRSS4 Transmembrane protease serine 4 0.988 landscape →
Q7M761 — 0.988 Q7M761 →
Q58L93 — 0.988 Q58L93 →
Q7RTY7 — 0.988 Q7RTY7 →
P49150 — 0.988 P49150 →
TMPRSS6 Transmembrane protease serine 6 0.987 landscape →
P79953 — 0.987 P79953 →